King Pharmaceuticals KG Operating Lease Weighted Average Discount Rate Percent

Operating Lease Weighted Average Discount Rate Percent at other companies

SiriusPointSPNT

——

W.R. BerkleyWRB

——

Silvercrest Asset Management GroupSAMG

——

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Operating cash flow-$15.1M-1,628%

Market cap$70.42M-71.3%

Enterprise value$184.93M-52.3%

P/E1.2×—

P/S1.6×-27.7×

Net margin131.5%—

Return on equity90.8%—

Debt / equity1.5×—

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent.

The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is King Pharmaceuticals's operating lease weighted average discount rate percent?: King Pharmaceuticals (KG) reported operating lease weighted average discount rate percent of $0.07 in Q1 2026.